KR-31831, benzopyran derivative, inhibits VEGF-induced angiogenesis of HUVECs through suppressing KDR expression.
Int J Oncol
; 32(6): 1311-5, 2008 Jun.
Article
en En
| MEDLINE
| ID: mdl-18497993
Angiogenesis is important in the development and progression of cancer, therefore the therapeutic approach based on anti-angiogenesis may represent a promising therapeutic option. KR-31831 is a novel anti-ischemic agent. Previously, we reported the anti-angiogenic activity of KR-31831. In the present study we investigated the molecular mechanisms underlying anti-angiogenic activity of KR-31831. We show that KR-31831 inhibits vascular endothelial growth factor (VEGF)-induced proliferation and tube formation via release of intracellular Ca2+ and phosphorylation of extra-cellular regulated kinase 1/2 (Erk 1/2) in human umbilical vein endothelial cells (HUVECs). Moreover, the expression of VEGF receptor 2 (VEGFR2, known as Flk-1 or KDR) was reduced by the treatment of KR-31831. These results suggest that KR-31831 may have inhibitory effects on tumor angiogenesis through down-regulation of KDR expression.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Benzopiranos
/
Endotelio Vascular
/
Receptor 2 de Factores de Crecimiento Endotelial Vascular
/
Factor A de Crecimiento Endotelial Vascular
/
Imidazoles
/
Neovascularización Patológica
Límite:
Humans
Idioma:
En
Revista:
Int J Oncol
Asunto de la revista:
NEOPLASIAS
Año:
2008
Tipo del documento:
Article
Pais de publicación:
Grecia